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Abstract
Background: Dendritic cells (DCs) are the most potent antigen-presenting cell population for activating tumor-
specific T cells. Due to the wide range of methods for generating DCs, there is no common protocol or defined
set of criteria to validate the immunogenicity and function of DC vaccines.
Methods: Monocyte-derived DCs were generated during 4 days of culture with recombinant granulocyte-
macrophage colony stimulating factor and interleukin-4, and pulsed with tumor lysate produced by hypochlorous
acid oxidation of tumor cells. Different culture parameters for clinical-scale DC preparation were investigated,
including: 1) culture media; 2) culture surface; 3) duration of activating DCs with lipopolysaccharide (LPS) and
interferon (IFN)-gamma; 4) method of DC harvest; and 5) cryomedia and final DC product formulation.
Results: DCs cultured in CellGenix DC media containing 2% human AB serum expressed higher levels of
maturation markers following lysate-loading and maturation compared to culturing with serum-free CellGenix DC
media or AIM-V media, or 2% AB serum supplemented AIM-V media. Nunclon™Δ surface, but not Corning
® tissue-
culture treated surface and Corning
® ultra-low attachment surface, were suitable for generating an optimal DC
phenotype. Recombinant trypsin resulted in reduced major histocompatibility complex (MHC) Class I and II
expression on mature lysate-loaded DCs, however presentation of MHC Class I peptides by DCs was not impaired
and cell viability was higher compared to cell scraping. Preservation of DCs with an infusible cryomedia containing
Plasma-Lyte A, dextrose, sodium chloride injection, human serum albumin, and DMSO yielded higher cell viability
compared to using human AB serum containing 10% DMSO. Finally, activating DCs for 16 hours with LPS and IFN-
g stimulated robust mixed leukocyte reactions (MLRs), and high IL-12p70 production in vitro that continued for 24
hours after the cryopreserved DCs were thawed and replated in fresh media.
Conclusions: This study examined criteria including DC phenotype, viability, IL-12p70 production and the ability to
stimulate MLR as metrics of whole oxidized tumor lysate-pulsed DC immunogenicity and functionality. Development
and optimization of this unique method is now being tested in a clinical trial of autologous oxidized tumor lysate-
pulsed DC in clinical-scale in recurrent ovarian, primary peritoneal or fallopian tube cancer (NCT01132014).
Background
Dendritic cells (DCs) are under clinical investigation as
a form of cancer therapy due to their unique ability to
elicit tumor-specific T cell responses. Encouraging
immunologic and therapeutic responses have been
observed in cancer patients treated with DC vaccines,
leading to an increased interest in developing protocols
for clinical-scale production of DCs for the clinic.
Human DCs exist in many different subsets. Monocyte-
derived DCs (MoDCs) are the most commonly used DC
subset in the clinic [1-3] as it is relatively easy to obtain
billions of monocytes from peripheral blood mononuc-
lear cells (PBMCs) collected by leukapheresis. Several
methods are available to enrich monocytes from
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separation and elutriation. In particular, the use of a
counter-current centrifugal elutriation system that can
process up to 20 × 10
9 PBMCs within one hour, is
extremely convenient for clinical-scale isolation of
monocytes and subsequent generation of DCs for clini-
cal trials [2-4]. This approach can also be easily per-
formed in conformity with Good Manufacturing
Practice (GMP) guidelines, circumvents the need for
multiple blood drawings from patients to generate suffi-
cient DCs, and saves time and expense by eliminating
plastic adherence or magnetic selection steps [5-7].
In many previous clinical trials of DC vaccines, DCs
were cultured for 7 days before antigen loading, matura-
tion and administration [8-15]. Reducing the time, labor
and expense for DC generation is necessary to move DC
vaccines to later phase clinical trials [16-18]. To this
end, we have recently demonstrated that MoDCs cul-
tured from an elutriated leukapheresis product for 4
days (Day-4 DCs) and pulsed with UVB-irradiated or
freeze-thawed tumor cell lysate, produced higher levels
of IL-12p70 and IP-10 upon activation with bacterial
lipopolysaccharide (LPS) and interferon (IFN)-g com-
pared to MoDCs cultured for 2 or 7 days [Cheryl L-L,
Chiang, Andrea R. Hagemann, Rachel Leskowitz, Rose-
marie Mick, Thomas Garrabrant, Brian J. Czerniecki,
Lana E. Kandalaft, Daniel J. Powell Jr. and George Cou-
kos: Day 4 myeloid-derived dendritic cells pulsed with
whole tumor lysate are highly immunogenic and elicited
potent anti-tumor responses, submitted]. Moreover,
these mature lysate-loaded Day-4 DCs were highly
immunogenic and stimulated the strongest allogeneic T
cell proliferation, while inducing equally potent specific
anti-ovarian tumor responses as Day-7 ‘classical DCs’ in
T cells obtained from healthy volunteers and ovarian
cancer patients
Whole tumor cells are a suitable source of tumor anti-
gens for loading DCs in order to prime both CD4
+ T
helper and CD8
+ cytotoxic T cells [19]. As whole tumor
lysates provide the full repertoire of characterized and
uncharacterized tumor-associated antigens for both CD4
+ and CD8
+ T cells, this allows for parallel presentation
of antigens to both T cell types to generate stronger pri-
mary immune responses and to prevent the emergence
of tumor escape variants. In addition, the presence of
CD4
+ T cells helps in promoting long-term CD8
+ Tc e l l
memory [20-22]. Previous work has investigated the use
of necrotic whole tumor cells as a source of antigens for
DCs. In particular, hypochlorous acid (HOCl) was used
to induce tumor cell necrosis and enhance the immuno-
genicity of tumor cells [23,24]. MoDCs readily engulfed
HOCl-oxidized SKOV3 ovarian tumor cells, and when
matured with either monophosphoryl lipid A or anti-
CD40 activating antibody, they could stimulate strong T
cell responses directed against specific ovarian tumor-
associated antigens such as HER-2/neu and MUC1. On
the other hand, MoDCs loaded with tumor cells killed
with non-oxidative methods such as heat or hydrochlo-
ric acid (HCl) did not prime ovarian-specific T cell
responses. These results were further supported by a
mouse melanoma model where mice vaccinated with
bone marrow-derived DCs loaded with oxidized syn-
geneic B16.F10 melanoma cells developed a T cell
response against melanoma and specifically against tyro-
sinase-related peptide 2. These tumor-specific responses
were not seen in mice treated with bone marrow-
derived DCs loaded with heat- or HCl-killed B16.F10
melanoma [25].
With these encouraging results, preparations were
made to take Day-4 MoDCs, loaded with HOCl-oxidized
autologous ovarian tumor cells, to the clinic. This study
sought to optimize the various production parameters,
such as the type of media and culture vessels for DC
generation, method of harvesting mature tumor lysate-
loaded DCs, and freezing methods of these DCs as an
‘off-the-shelf’ vaccine product. It also aimed to examine
and define parameters for optimal DC vaccine produc-
tion and potency assessment such as DC phenotype, IL-
12p70 production, and mixed leukocyte reactions
(MLRs). The following findings have facilitated the
development of a protocol for clinical-scale production
of DC-whole tumor lysate vaccines currently being eval-
uated in a clinical trial in ovarian, peritoneal and fallo-
pian tube cancers.
Materials and methods
Generation of DCs from fresh monocytes
For research-scale experiments, DCs were prepared
from fresh PBMCs obtained from 6 healthy donors who
had given written informed consent to an Institutional
Review Board (IRB)-approved tissue procurement study
at the University of Pennsylvania Human Immunology
Core Facility. Monocytes from PBMCs were isolated by
negative selection using the RosetteSep
® Human Mono-
cyte Enrichment Cocktail kit (STEMCELL Technologies
Inc., Vancouver, Canada) and cultured at 1 × 10
6 cells/
ml in serum-free AIM-V media (therapeutic grade; Invi-
trogen, Carlsbad, CA) supplemented with 2 mM L-glu-
tamine, 100 units/ml penicillin, and 100 μg/ml
streptomycin (all from Cellgro, Manassas, VA), or in
AIM-V media containing 2% human AB serum (Valley
Biomedical Inc., Winchester, VA). Additional media
tested included serum-free CellGenix DC media (GMP
grade; CellGenix Technologie Transfer GmbH, Freiburg,
Germany) that was supplemented with 2 mM L-gluta-
mine, 100 units/ml penicillin and 100 μg/ml streptomy-
cin, or CellGenix DC media containing 2% human AB
serum. Monocytes were cultured in the presence of
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phage colony stimulating factor (GM-CSF; 500 or 1000
IU/ml) and interleukin-4 (IL-4; 250 or 500 IU/ml), both
purchased from PeproTech (Rocky Hill, NJ). For clini-
cal-scale DC preparations, fresh elutriated monocytes
were obtained from PBMCs of 2 different healthy
donors in the Clinical Cell and Vaccine Production
Facility (CVPF) at the Hospital of the University of
Pennsylvania. Monocytes were cultured using Nun-
clon™Δ Surface 1-tray Cell Factories at 1 × 10
6 cells/ml
in CellGenix DC media containing 2% human AB
serum, recombinant clinical grade GM-CSF (Leukine
®,
Bayer Healthcare Pharmaceuticals, Wayne, NJ) and ani-
mal-free research grade IL-4 (R&D Systems, Inc., Min-
neapolis, MN).
At the end of the 4-day culture period, the surface
expression of CD11c, CD14 and HLA-DR on these dif-
ferentiated immature DCs were determined and the pur-
ity was found to be >98%. HOCl-oxidized SKOV3 lysate
was added to the DCs at a cell ratio of 1:1 for 20 to 24
h in the presence of fresh GM-CSF (500 IU/ml, of same
origin as above depending on the culture scale). On day
5, lysate-loaded DCs were activated with LPS (60 EU/
ml) and IFN-g (2000 IU/ml) for 6 to 16 h. In research-
scale DC preparations, research grade LPS (Escherichia
coli; Sigma-Aldrich Corp.) and research grade IFN-g
(PeproTech, Rocky Hill, NJ) were used. For activation of
clinical-scale DC cultures, we used clinical grade IFN-g
(Intermune, San Francisco, CA) and clinical grade LPS
(Escherichia coli O:113; U.S. Standard Reference Endo-
toxin) which was a kind gift from Dr. Anthony Suffre-
dini from the Clinical Center, National Institutes of
Health, Bethesda, MD.
On day 6, mature lysate-loaded DCs were harvested,
and analyzed for their phenotype and IL-12p70 produc-
tion. In addition, DCs were cryopreserved at 5 × 10
6
cells/ml for further use. Before transitioning to clinical-
scale cell factory culture system, optimal DC culture
conditions were determined by setting up multiple
research-scale DC preparations in T25 cm
2 tissue cul-
ture flasks that had the same coated-surface properties
as the cell factories. Nunclon™Δ Surface T25 cm
2 tissue
culture flasks with filter caps and Nunclon™Δ Surface
1-tray Cell Factories were purchased from Thermo
Fisher Scientific Inc., Rochester, NY, USA. Corning
® cell
culture T25 cm
2 tissue culture flasks with vented caps
and Corning
® cell culture ultra-low attachment T25
cm
2 tissue culture flasks with vented caps were obtained
from Sigma-Aldrich Corp., St. Louis, MO.
HOCl-oxidation of whole tumor cells and preparation of
tumor lysate




+,M U C 1
+. It was maintained in DMEM that
was supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Invitrogen), 2 mM L-glutamine, 100
units/ml penicillin, and 100 μg/ml streptomycin (all
from Cellgro), and was routinely tested to be free of
Mycoplasma. Treatment of SKOV3 tumor cells with
HOCl has been previously described [23,24]. Briefly, 60
μM of HOCl solution was prepared by diluting the
stock sodium hypochlorite solution (NaOCl, reagent
grade, available chlorine 10-15%; Sigma-Aldrich Corp.)
with DPBS (Cellgro) and added immediately to SKOV3
tumor cells at a cell density of 1 × 10
6/ml. The tumor
cell suspension was incubated for 1 h at 37°C, 5% CO2
with gentle agitation after every 30 min to induce oxida-
tion-dependent tumor cell death. After that, tumor cells
were harvested, washed twice with DPBS and resus-
pended at 1 × 10
7 cells/ml in appropriate DC media for
6 cycles of freeze (either with dry ice for ≥ 20 min or at
-80°C for ≥ 1 h) and thaw at room temperature to com-
plete fragmentation (determined by Trypan blue stain-
ing) before loading onto DCs.
DC harvesting
After stimulation with LPS and IFN-g for 6 to 16 h,
some of the mature lysate-loaded DCs were harvested
using either TrypLE™ Select animal-free tyrpsin repla-
cement (Gibco, Carlsbad, CA) or with cold DPBS and
cell scrapers (BD Falcon™, San Jose, CA). For harvest-
ing with TrypLE™ Select animal-free tyrpsin replace-
ment, cell culture media was removed and cells
incubated with 1 ml of TrypLE™ Select per T25 cm
2
flask at 37°C, 5% CO2 for 5 to 10 min. Then the cells
were collected by gentle tapping and washed twice with
DPBS before use. For harvesting with cold DPBS and
cell scraping, cell culture media was first removed and 5
ml of cold DPBS was added to each T25 cm
2 flask. The
DC cultures were incubated at 4°C for 30 min and a cell
scraper used to remove the remaining attached DCs.
DCs were then washed twice with DPBS before use.
DC phenotyping
After coculturing DCs with HOCl-oxidized SKOV3
lysate for 20 to 24 h, LPS and IFN-g were added for 16
h before harvesting the DCs for phenotypic analysis.
DCs were harvested using TrypLE™ Select animal-free
trypsin replacement or cold DPBS with scraping as
described above. DCs were washed twice with DPBS
and resuspended in cold staining buffer (DPBS contain-
ing 2% heat-inactivated FBS) for 10 min blocking on ice.
DCs were stained with APC-conjugated anti-HLA-DR
[clone G46-6, mouse IGg2a, ;B DP h a r m i n g e n ,S a n
J o s e ,C A ] ,P E - c o n j u g a t e da n t i - C D 1 1 c[ c l o n eB - l y 6 ,
mouse IGg21, ;B DP h a r m i n g e n ] ,a n do n eo ft h ef o l -
lowing markers: a) CD1c [clone AD5-8E7, mouse IGg2a:
Miltenyi Biotech]; b) CD14 [clone M5E2, mouse IGg2a,
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IGg1, ; BD Pharmingen]; d) CD83 [clone HB15e,
mouse IGg1, ; BD Pharmingen]; e) CD86 [clone 2331
(FUN-1), mouse IGg1, ;B DP h a r m i n g e n ] ;f )C D 4 0
[clone 5C3, mouse IGg1, ;B DP h a r m i n g e n ] ;g )M H C
Class I [clone G46-2.6, mouse IGg1, ; BD Pharmingen];
h) CCR7 [clone 3D12, rat IGg2a, ; BD Pharmingen], or
i) isotype controls (PE-, APC-, or FITC-conjugated
mouse/rat IgG, ; BD Pharmingen) for 30 min on ice.
Cells were washed twice with staining buffer before ana-
lysis. For DC-LAMP expression, DCs were first stained
with FITC-conjugated anti-HLA-DR and then subjected
to fix-permeabilization treatment for 30 min at 4°C, and
followed by intracellular staining with APC-conjugated
anti-DC LAMP [clone I10-1112, mouse IGg1, ;B D
Pharmingen] for another 30 min on ice. Cells were
washed twice with staining buffer and acquired on the
same day on a BD Canto flow cytometer or BD Calibur
(Becton Dickinson, Franklin Lakes, NJ). Data were ana-
lyzed using the Pro CellQuest software. DCs were first
gated using the forward and side scatter dot plots, and
the cell population highly expressing HLA-DR and
CD11c was further analyzed for CD1c, CD14, CD80,
CD83, CD86, CD40, CCR7, MHC Class I and DC-
LAMP.
IL-12p70 production by DC
DCs were cocultured with HOCl-oxidized SKOV3 lysate
at a ratio of 1 DC to 1 tumor cell for 20 to 24 h at 37°
C, 5% CO2. Fresh GM-CSF (500 IU/ml) was added to
facilitate tumor lysate uptake by the DCs. Then 60 EU/
ml of LPS and 2000 IU/ml of IFN-g were added to the
cocultures for 6 to 16 h to stimulate DC maturation.
Supernatants of cocultures were collected by centrifuga-
tion and analyzed for IL-12p70 (i.e. IL-12p70 from fresh
DCs). DCs from cocultures were also collected and
washed twice with DPBS for further use. One half of
these DCs were replated at 1 × 10
6 cells/ml in fresh
complete CellGenix DC media supplemented with 2%
human AB serum for a further 24 h to analyze for IL-
12p70 (i.e. IL-12p70 from fresh replated DCs). The
o t h e rh a l fo ft h eD C sw e r ef r o z e ni na ni n f u s i b l ec r y o -
media or 90% human AB serum and then thawed for
replating at 1 × 10
6 cells/ml in fresh complete CellGenix
DC media supplemented with 2% human AB serum for
24 h to analyze for IL-12p70 (i.e. IL-12p70 from thawed
replated DCs). IL-12p70 concentration was determined
with ELISA according to the manufacturer’sp r o t o c o l
(BioLegend, San Diego, CA). Briefly, NUNC MaxiSorp™
96-well ELISA plates (Thermo Fisher Scientific, Wal-
tham, MA) were coated with 1 × capture IL-12p70 for 2
h at 37°C, 5% CO2 or overnight at 4°C. Then, plates
were washed 4 times with wash buffer (DPBS containing
0.05% Tween 20) using the ELISA plate washer (BioTek,
Winooski, VT). Supernatants were diluted appropriately
with 1x assay diluent (BioLegend) and incubated over-
night at 4°C. The next day, the plates were washed 5
times with wash buffer and 1 × biotinylated detection
antibody of IL-12p70 was added for 1 h incubation at
room temperature. Plates were then washed 5 times
with wash buffer and incubated with alkaline phospha-
tase-conjugated streptavidin for 30 min at room tem-
perature. Five further washes with wash buffer were
done and TBM substrate solution was added for 15
min. The reactions were stopped by adding equal
volume of 1 N sulfuric acid (Fisher Scientific, Lawn, NJ).
Plates were read using the ELISA plate reader (BioTek)
and results expressed as pg/ml.
IFN-g intracellular staining
In some experiments, HER-2/neu or MART-1 specific T
cells were used to assess the ability of DCs to present
cognate antigen. HER-2/neu specific T cells were iso-
l a t e df r o ma nH L A - A 2
+ patient with breast cancer pre-
viously vaccinated with HLA-A2 restricted HER-2/neu
peptides including HER-2/neu369-377 (KIFGSLAFL) [26].
HER-2/neu specific T cells were expanded by two
rounds of incubation with MoDCs derived from HLA-
A2
+ donors pulsed with HER-2/neu369-377.T h ef r e -
quency of HER-2/neu specific CD8 T cells in output T
cells was 3-4%. MART-1 specific T cells were derived
from tumor-reactive tumor-infiltrating lymphocytes after
long-term culture in the presence of human recombi-
nant IL-2, and were a kind gift of Dr. Stephen Rosen-
berg (Surgical Branch, National Cancer Institute,
Bethesda, MD) [27].
DCs derived from HLA-A2
+ individuals were cocul-
tured with HOCl-oxidized SKOV3 lysate at 1:1 cell ratio
f o r2 0t o2 4ha t3 7 ° C ,5 %C O 2 in the presence of fresh
500 IU/ml of GM-CSF. Then DCs were stimulated with
60 EU/ml of LPS and 2000 IU/ml of IFN-g for 16 h.
Two hours before the end of the LPS and IFN-g stimu-
lation (i.e. 14 h post-stimulation), DCs were pulsed with
either HLA-A2 restricted HER-2/neu369-377 or MART-
126-35 (EAAGIGILTV) [28] peptides (both from Ameri-
can Peptide Company, Inc., Sunnyvale, CA; ≥97% pure
as determined by reverse-phase high performance liquid
chromatography) at different concentrations (i.e. 0.1, 1
or 10 μg / m l )o rw i t hm e d i a( i . e .u n p u l s e df o rt h el a s t2
h). Following that, DCs were harvested and cocultured
with HER-2/neu or MART-1 specific T cell lines for a
total of 5 h. After the 1
st hour of the total 5 h incuba-
tion, GolgiStop containing brefeldin A (1000x dilution
according to manufacturer’s instructions; BD Pharmin-
gen) was added to the cocultures for the remainder of
the incubation period. T cells were then harvested and
stained for PE-Cy7-conjugated anti-CD8 (clone RPA-T8,
mouse IgG1, ; BD Pharmingen) followed by fix-
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for 30 min at 4°C to stain intracellularly for IFN-g (anti-
IFN-g PE-conjugated monoclonal antibody, clone 4S.B3,
mouse IgG1, ;B DP h a r m i n g e n ) .T h e nc e l l sw e r e
washed twice with staining buffer (DPBS containing 2%
heat-inactivated FBS), collected on the same day and
interrogated using BD Canto flow cytometer (Becton
Dickinson). Data were analyzed with Pro CellQuest soft-
ware. T cells that were double-positive for CD8
+ and
IFN-g were expressed as a percentage of all the CD8
+ T
cells.
Cryopreservation and storage of mature lysate-loaded
DCs
DCs that had been loaded with HOCl-oxidized SKOV3
lysate and subsequently matured with 60 EU/ml LPS
and 2000 IU/ml IFN-g for 6 to 16 h were cryopreserved
at 5 × 10
6 DCs per ml of either a) infusible cryomedia
that contained the following components in final con-
centrations: 31.25% Plasma-Lyte A, 31.25% D51/2NS
(5% dextrose, 0.45% sodium chloride), 5% human serum
albumin (HSA); 1% Dextran 40 (10% low molecular dex-
tran in 5% dextrose), and 7.5% dimethyl sulfoxide
(DMSO). Plasma-Lyte A injection (USP) and HSA were
purchased from Baxter, Deerfield, IL. D51/2NS (USP)
and low molecular dextran in 5% dextrose injection
were obtained from Abbott Laboratories, North Chi-
cago, IL. Cryoserve brand of DMSO was manufactured
by Ben Venue Laboratories, Inc., Bedford, OH; or b)
human AB serum (Valley Biomedical Inc.) containing
10% Hybri-Max™ sterile-filtered DMSO (Sigma-Aldrich
Corp). The cells were frozen in a controlled-rate gradi-
ent freezer (model Forma 8018; Thermo Scientific,
Asheville, NC).
Cell viability
Cell viability was determined by Trypan Blue staining
using a Bürker chamber (Paul Marienfeld GmbH & Co.
KG, Lauda-Königshofen, Germany) and inverted phase
microscope (Leica, Wetzlar, Germany). The % viable
DCs was determined by expressing the number of live
DCs as a percentage of the total number of DCs
counted in the 4 big squares of the Bürker chamber.
Mixed leukocyte reactions
DCs were cocultured with HOCl-oxidized SKOV3 lysate
at a cell ratio of 1:1 for 20 to 24 h at 37°C, 5% CO2 in
t h ep r e s e n c eo ff r e s h5 0 0I U / m lo fG M - C S F .F o l l o w i n g
that, 60 EU/ml of LPS and 2000 IU/ml of IFN-g were
added to the cocultures for 16 h to stimulate DC
maturation. Then the cocultures were harvested, washed
twice with DPBS and seeded in 96-well round bottom
plates at 2.5 × 10
3,5×1 0
3 or 1 × 10
4 DCs/well. Allo-
geneic CD3
+ T cells from 3 different donors were added
to the DCs at 1 × 10
5 cells/well. The cells were cultured
for a total of 7 days at 37°C, 5% CO2. For the final 16 h
of coculture, 1 μCi [
3H] thymidine (ICN Biomedical,
Costa Mesa, CA) was added. T cell proliferation was
measured by liquid scintillation counting (Microbeta
Systems; Immunotox, Richmond, VA). All assays were
performed in triplicate. Control wells were set up to
contain unpulsed immature DCs alone, unpulsed mature
DCs alone or T cells alone. Results were expressed as
counts per minute.
Statistical analysis
Means for different experimental groups were analyzed
from 3 to 6 independent experiments (i.e. DCs from 3
to 6 different individuals). The analysis of significance
was carried out using unpaired Student’s t tests or one-
way ANOVA. A significance level of 0.05 or less was
considered statistically significant.
Results
Optimization of culture media and cytokine
concentrations
AIM-V and CellGenix DC media are two widely used
clinical grade serum-free defined media for generating
DCs [29-31]. Serum has been shown to improve DC dif-
ferentiation and function [32] but the use of FBS could
lead to transmission of bovine-related infectious agents,
and the presence of serum contaminants could affect
human DC differentiation and generate anti-bovine
immunoreactivity that adversely impact administering
multiple vaccinations [33-35]. Autologous serum is a
possibility but the serum of cancer patients might con-
tain high levels of inhibitory cytokines such as IL-6 [36]
or IL-10 [37] that could affect DC function. Pooled
human AB serum is a suitablea l t e r n a t i v e ,w h e r eo n e
batch of human AB serum can be used for an entire
clinical trial to avoid batch-to-batch variation. Therefore,
AIM-V and CellGenix DC media with or without 2%
human AB serum for culturing DCs were compared.
Research-scale DC preparations were set up by seeding
each T25 cm
2 NUNC Surface flasks with 1 × 10
6
healthy donor monocytes/ml media (a total of 5 × 10
6
monocytes per flask). After 4 days of culture, DCs were
loaded with HOCl-oxidized SKOV3 lysate for ~20 h,
and matured with LPS and IFN-g for ~16 h. DCs gener-
ated under the four different media conditions had over-
all comparable immunophenotypes, although DCs that
were cultured with AB serum-supplemented CellGenix
DC media exhibited the highest DC-LAMP (P =0 . 0 4 ;
one-way ANOVA) amongst all DCs, and expressed sig-
nificantly higher CD86 (P = 0.05) when compared to
DCs grown in serum-free CellGenix DC media [Figure
1A]. In addition, CD14 expression was significantly
lower on DCs cultured in serum-supplemented media
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= 0.004; CellGenix DC media, P =0 . 0 4 )[ F i g u r e1 B ] .
There were no significant differences in the amount of
IL-12p70 protein secreted by DCs grown in the 4 differ-
ent media conditions (P = 0.2; one-way ANOVA, Figure
1C).
Next, we analyzed the effect of different media on DC
viability (Table 1). Viable DCs were counted (by Trypan
blue exclusion) at the completion of four days of GM-
CSF and IL-4 differentiation and then again at the end
of pulsing with lysate and maturation with LPS and
IFN-g. CellGenix DC media containing 2% AB serum
gave the highest final number of viable DCs compared
to other media conditions (P = 0.016; one-way ANOVA,
Table 1). These results collectively indicated that DCs
cultured with CellGenix DC media containing 2% AB
serum had a favorable immunophenotype of low CD14,
high CD86 and DC-LAMP, high IL-12p70 capability,
and high cell viability. Based on these results and the
reported superior DC differentiation and function in the
presence of serum [32], and the availability of CellGenix
DC media in GMP grade, CellGenix DC media supple-
mented with 2% human AB serum was chosen as the
leading media candidate for all subsequent experiments.
Next, we investigated the effect of different concentra-
tions of recombinant GM-CSF (500 or 1000 IU/ml) and
IL-4 (250 or 500 IU/ml) on DC differentiation and phe-
notype (Figure 1D). The levels of HLA-DR (black bar)
Figure 1 Comparison of the phenotype and IL-12p70 production of mature HOCl-oxidized lysate-loaded DCs generated in human AB
serum-free or serum-containing AIM-V and CellGenix DC media, and supplementation with different concentrations of GM-CSF and
IL-4. (A-B) DCs cultured in CellGenix DC media containing 2% human AB serum displayed a desirable phenotype with the highest level of DC-
LAMP (*P = 0.005; one-way ANOVA) when compared to DCs cultured in other media conditions, and significantly higher CD86 (*P = 0.05) and
lower CD14 (*P = 0.04) when compared to DCs cultured in serum-free CellGenix DC media. (C) DCs generated in CellGenix DC media plus 2%
human AB serum produced slightly, though not significantly, higher amount of IL-12p70 compared to DCs generated in other media conditions
(P = 0.2; one-way ANOVA). (D) 500 IU/ml recombinant GM-CSF and 250 IU/ml recombinant IL-4 were sufficient concentrations for generating a
favorable immature DC phenotype with low CD14, and intermediate HLA-DR and CD1c. All the data presented were the mean of 6 independent
experiments (i.e. DCs from 6 different individuals) in research-scale cultures in Nunclon™Δ Surface T25 cm
2 flasks ± standard error of the mean
(SEM). P values were determined with unpaired Student’s t test unless otherwise stated. * denoted that P values were significant.
Chiang et al. Journal of Translational Medicine 2011, 9:198
http://www.translational-medicine.com/content/9/1/198
Page 6 of 16and CD11c expression (white bar) were similar on
immature DCs in all the conditions tested. No signifi-
cant difference in CD14 (grey bar) expression was
observed on DCs that were cultured in any of the condi-
tions (P = 0.42, one-way ANOVA; Figure 1D). Thus, 500
IU/ml GM-CSF and 250 IU/ml IL-4 were selected for
use in all subsequent DC preparations.
Optimization of Culture Flasks
Cell factories are suitable for clinical-scale production of
DCs for their large surface areas and as closed-cell cul-
ture systems to minimize product contamination. As
each brand of cell factory might have different surface
coating properties that could affect DC differentiation
and maturation, three commercially available cell fac-
tories were evaluated - 1) Nunclon™Δ Surface 1-tray
Cell Factories; 2) Corning
® CellSTACK
® culture cham-
bers; and 3) Corning
® cell culture ultra-low attachment
CellSTACK
® chamber. For ease of handling multiple
DC preparations and assessing the reproducibility of the
DC cultures, multiple research-scale DC preparations
were set up in T25 cm
2 tissue culture flasks that had
the same surface coating properties as the above cell
factories. DCs were cultured in CellGenix DC media
containing 2% human AB serum in all culture flasks,
loaded with tumor lysate and matured with LPS and
IFN-g as described above. In Figure 2A, it was observed
that DCs cultured in Nunclon™Δ Surface flasks (surro-
gate of Nunclon™Δ Surface 1-tray Cell Factories) exhib-
ited an overall favorable immunophenotype with
significantly higher DC-LAMP (P = 0.003) and lower
CD14 (P = 0.01) when compared to DCs cultured in
Corning




Next, Nunclon™Δ Surface was compared to Corning
®
cell culture ultra-low attachment surface for generating
DCs. Since Corning
® cell culture ultra-low attachment
T25 cm
2 flasks (surrogate of Corning
® ultra-low attach-
ment cell factory chambers) have hydrophilic and
neutrally charged surface to inhibit cell attachment, it
was hypothesized that this could facilitate easier DC
harvesting compared to polystyrene Nunclon™Δ Sur-
face. DCs were loaded with tumor lysate, and stimulated
with LPS and IFN-g as described above. Then, DCs
were harvested with TrypLE™ Select and washed twice
with DPBS before further analysis. DCs generated in
Corning
® ultra-low attachment surface expressed signifi-
cantly lower CD86 (P = 0.011) and HLA-DR (P =
0.0004) when compared to DCs generated in Nun-
clon™Δ Surface (Figure 2B). DCs generated in Corn-
ing
® cell culture ultra-low attachment surface were also
smaller in size (data not shown) when compared to DCs
cultured in Nunclon™Δ Surface flasks. These results
s u g g e s t e dt h a tD C sg e n e r a t e di nC o r n i n g
® cell culture
ultra-low attachment surface did not mature as effi-
ciently in the presence of LPS and IFN-g when com-
pared to DCs cultured in Nunclon™Δ Surface.
Nunclon™Δ Surface seemed to provide a suitable stra-
tum for DC maturation and was chosen as the preferred
vessel to generate DCs in subsequent experiments.
Optimization of DC harvest
It was observed that approximately 50% of the Day-4
differentiated, immature and unpulsed DCs that were
generated using Nunclon™Δ Surface (both T25 cm
2
flasks and 1-tray Cell Factories) in combination with
CellGenix DC media supplemented with 2% human AB,
would adhere firmly to the flask or cell factory surface
(data not shown). After lysate loading and stimulation
with LPS and IFN-g, most DCs were firmly attached to
the flask or chamber surface. Hence, a means to harvest
these DCs was required. Two commonly used methods
for harvesting mature lysate-pulsed DCs were evaluated:
1) by enzymatic mobilization using TrypLE™ Select, a
recombinant fungal serine protease with trypsin-like
activity derived from microbial fermentation (incubated
for up to 10 min at 37°C); or 2) physical mobilization by
incubation with cold DPBS for 30 min at 4°C followed
Table 1 DC viability following culture in four different media.
Number of viable DCs harvested from 5 × 10
6 monocytes per T25 cm2 flask
Media condition Before lysate-loading and maturation
(10
6)
After lysate-loading and maturation
(10
6)
% viable DC generated (±
SEM)
AIM-V no AB serum 4.52 ± 0.88 2.29 ± 0.36 53.39 ± 5.94
AIM-V + 2% AB serum 5.10 ± 0.92 3.05 ± 0.3 64.72 ± 7.14
CellGenix no AB serum 5.09 ± 0.61 2.76 ± 0.87 43.64 ± 6.17
CellGenix + 2% AB
serum
5.48 ± 0.67 3.87 ± 0.35 73.28 ± 7.58*
CellGenix DC media supplemented with 2% human AB serum yielded the highest percentage of viable DCs after loading with HOCl-oxidized lysate (1 DC to 1
tumor cell ratio for 20-24 h) and 16 h maturation with LPS (60 EU/ml) and IFN-g (2000 IU/ml). The final percentage of viable DC generated was calculated as
follows: (number of viable DCs obtained per flask after lysate-loading and maturation ÷ number of viable DCs obtained per flask before lysate-loading and
maturation) × 100%. The mean of 6 independent experiments ± standard error of the mean [SEM]) is shown. *P = 0.016; final % of viable DCs generated from
CellGenix + 2% AB serum was significantly different from the final % of viable DCs generated with AIM-V no AB serum, AIM-V + 2% AB serum or CellGenix no AB
serum (one-way ANOVA).
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Page 7 of 16by scraping. This experiment was conducted in Nun-
clon™Δ Surface T25 cm
2 flasks; DCs were loaded with
oxidized whole tumor lysate followed by stimulation
with LPS and IFN-g as described above, and finally har-
vested for analysis. In Figure 3A, lysate-loaded, mature
DCs that were harvested using TrypLE™ Select exhib-
ited a modest (~30%) but not significant reduction in
surface MHC Class I (P = 0.13) and HLA-DR expression
(P = 0.15) compared to DCs that were harvested using
cold DPBS and scraping. The levels of CD86, CD40 and
CD11c on enzymatically mobilized DCs were similar to
DCs mobilized using cold DPBS and scraping.
To determine whether enzymatic treatment affected
the DC ability to present antigens to T cells, DCs were
pulsed with HOCl-oxidized SKOV3 lysate and matured
with LPS and IFN-g.I nt h el a s t2ho ft h e1 6hD C
maturation, lysate-loaded DCs were also pulsed with
HLA-A2 restricted HER-2/neu369-377 or MART-126-35
peptides at different concentrations (0.1, 1 or 10 μg/ml).
DCs were harvested using TrypLE™ Select or by incu-
bation in cold DPBS for 30 min at 4°C and followed by
scraping. Harvested DCs were then cocultured for a
total of 5 h with HLA-A2
+ T cells that comprised a
measureable frequency of HER-2/neu specific T cells
(derived from PBL of a breast cancer patient previously
vaccinated with HER-2/neu369-377 [26]) or with MART-1
specific T cells [27]. DCs that had been harvested using
TrypLE™ Select presented HER-2/neu (Figure 3B, left
Figure 2 Comparison of the effect of Nunclon™Δ Surface, Corning
® cell-culture surface and Corning
® ultra-low attachment surface on
DC phenotype and differentiation. DC were cultured with CellGenix DC media containing 2% human AB serum in T25 cm
2 flasks that had the
same surface properties as one of the three commercially available cell factories - Nunclon™Δ Surface 1-tray Cell Factories, Corning
® CellSTACK
®
culture chambers or Corning
® cell culture ultra-low attachment CellSTACK
® chamber. DC phenotype was evaluated following lysate-loading and
maturation for 16 h with LPS and IFN-g. (A) DCs cultured in Nunclon™Δ Surface flasks (surrogate of Nunclon™Δ Surface 1-tray Cell Factories)
exhibited an overall favorable immunophenotype with significantly higher DC-LAMP (**P = 0.003) and lower CD14 (*P = 0.01) when compared
to DCs cultured in Corning
® cell-culture surface flasks (surrogate of Corning
® CellSTACK
® culture chambers). Data were the mean of 6
independent experiments (i.e. DCs from 6 different individuals) in research-scale cultures ± SEM. (B) DCs that were cultured in Corning
® ultra-
low attachment surface (surrogate of Corning
® ultra-low attachment cell factory chambers) expressed significantly lower CD86 (**P = 0.011) and
HLA-DR (***P = 0.0004) following lysate-loading and maturation when compared to DCs cultured in Nunclon™Δ Surface (surrogate of
Nunclon™Δ Surface 1-tray Cell Factories) and treated the same way. Data were the mean of 3 independent experiments (i.e. DCs from 3
different individuals) in research-scale cultures ± SEM. P values were determined with unpaired Student’s t test. * denoted that P values were
highly significant.
Chiang et al. Journal of Translational Medicine 2011, 9:198
http://www.translational-medicine.com/content/9/1/198
Page 8 of 16panel) and MART-1 (Figure 3B, right panel) peptides as
efficiently as DCs that had been harvested with cold
DPBS and scraping. Both DCs could present exogenous
MART-1 peptides efficiently to CD8
+ T cells even at a
low peptide concentration (i.e. at 0.1 μg/ml) and there
was apparent saturation of MHC Class I sites at the
lowest peptide concentration, as no further increase in
IFN-g T cell response could be detected with higher
doses of either peptide [Figure 3B]. Importantly, DCs
loaded with HOCl-oxidized SKOV3 ovarian tumor lysate
but not pulsed with peptides efficiently presented endo-
genous HER-2/neu antigen to HER-2/neu specific CD8
+
T cells (but not to MART-1 specific CD8
+ T cells) [Fig-
ure 3B, left and right bottom panels], consistent with
expression of HER-2/neu by SKOV3 cells. Neither T
cells alone nor T cells cocultured with unpulsed DCs
produced any IFN-g (data not shown). These results
show that DC enzymatic mobilization using TrypLE™
Select did not did not affect the ability of DCs to pre-
sent class I restricted tumor-associated peptides.
Lastly, the viability of DCs mobilized with TrypLE™
Select or with cold DPBS and scraping was compared.
Table 2 shows that the percentage of viable DCs har-
vested with TrypLE™ Select was significantly higher (P
= 0.0003) compared to the more harsh method of har-
vesting DCs with cold DPBS and scraping. Thus, Try-
pLE™ Select is more suitable for mobilizing adherent
DCs for clinical applications.
Figure 3 Comparison of TrypLE™ Select animal-free tyrpsin immobilization and cold PBS with cell scraping for harvesting mature
HOCl-oxidized lysate-loaded DCs. (A) DCs were matured with LPS and IFN-g for 16 h following lysate-loading. It was observed that mature
lysate-loaded DCs that were harvested using TrypLE™ Select animal-free tyrpsin replacement exhibited approximately 30-40% reduction in the
levels of MHC Class I (P = 0.13; NS) and HLA-DR (P = 0.15; NS) compared to DCs that were harvested with cold DPBS and cell scraping. Data
were the mean of 3 independent experiments (i.e. DCs from 3 different individuals) ± SEM in research-scale Nunclon™Δ Surface T25 cm
2 flasks.
P values were determined with unpaired Student’s t test. NS indicated that P values were not significant. (B) Mature lysate-loaded DCs that were
harvested with TrypLE™ Select animal-free tyrpsin replacement were as efficient as DCs that were harvested with cold DPBS and cell scraping in
presenting MHC Class I-restricted HER-2/neu and MART-1 peptides and stimulating HER-2/neu and MART-1 CD8
+ T cells in intracellular IFN-g
assessments.
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To overcome the need of preparing fresh lysate-pulsed
DCs for each round of vaccination, freshly generated
DCs could be cryopreserved after pulsing and matura-
tion. DC stability was determined after cryopreserva-
tion in two types of cryomedia: 1) infusible cryomedia
that contained Plasma-Lyte A, dextrose, sodium chlor-
ide injection, human serum albumin, and DMSO, and
2) 90% human AB serum plus 10% DMSO. Elutriated
normal donor monocytes were cultured for 4 days in a
Nunclon™Δ Surface 1-tray Cell Factory at 1 × 10
6/ml
to a total of 200 million cells per cell factory. Then dif-
ferentiated DCs were loaded with HOCl-oxidized
SKOV3 lysate at 1:1 cell ratio for 20-24 h plus 500 IU/
ml GM-CSF, followed by 16 h stimulation with LPS
and IFN-g. After that, DCs were harvested using Try-
pLE™ Select and frozen in multiple aliquots at 5 × 10
6
DCs/ml cryopreservation media. Approximately 24 h
later, the DCs were thawed and cultured in CellGenix
DC media containing 2% human AB serum for 24 h
and analyzed for viability (Table 3). Both types of cryo-
media yielded similar high DC viability (92.9 ± 2.57%
from infusible cryomedia and 86.5 ± 0.55% for AB
serum with 10% DMSO, P = 0.6). The phenotype of
t h et h a w e dD C sw a sa n a l y z e db yg a t i n go n7 - A A D
negative viable cells (Figure 4A). DCs that had been
cryopreserved with infusible cryomedia (Figure 4A
middle column) retained similar levels of CD86 and
CD1c as compared with freshD C s( F i g u r e4 Al e f tc o l -
umn). HLA-DR surface expression on infusible cryo-
media-cryopreserved DCs was significantly reduced as
compared with fresh DCs (Figure 4B; P =0 . 0 0 1 ) .O n
the other hand, DCs that were cryopreserved with 90%
human AB serum plus 10% DMSO retained similar
levels of CD80, CD86, CD40, MHC class I and CD1c
as that of fresh DCs (Figure 4A third column). These
DCs had also significantly reduced levels of HLA-DR
(Figure 4B; P =0 . 0 0 4 ) .
Optimization of maturation length for DCs destined to
cryopreservation
Robust production of IL-12p70 is a critical determinant
of the potency of the DC vaccine in vivo.I th a sb e e n
shown to be essential for stimulating type I polarized T
cells and inducing tumor-specific cytotoxic T cells by
for tumor rejection [38-41]. Thus, the optimal time for
mobilization of lysate-pulsed DCs after exposure to LPS
and IFN-g stimulation in vitro was determined in order
to maximize the subsequent IL-12p70 production over
the next 24 h (theorizing that this would be the critical
period of T cell priming in vivo when DCs are injected
into patients). Research-scale DC preparations were set
up in Nunclon™Δ Surface T25 cm
2 flasks. After tumor
lysate-loading, the DCs were treated with LPS and IFN-
g for 6, 9, 12 or 16 h and the cell culture supernatants
collected for assessing IL-12p70 concentrations (there-
after called “fresh” DCs). These DCs were then har-
vested with TrypLE™ Select, thoroughly washed and
immediately replated for 24 h in fresh media (thereafter
called “fresh replated” DCs). Some DCs were frozen,
then thawed 24 h later and replated for a further 24 h
in fresh media (thereafter called “thawed replated” DCs).
IL-12p70 was measured in the supernatants of fresh,
fresh replated or thawed replated DCs. Fresh DCs
started to produce IL-12p70 at 6 h (Figure 5) and con-
tinued to increase IL-12p70 production at 12 h
(approximately 2000 pg/ml), and peaking at 16 h
(approximately 3500 pg/ml). Fresh replated DCs were
capable of producing IL-12p70 in the absence of further
LPS and IFN-g stimulation at levels comparable to fresh
DCs (Figure 5). Encouragingly, thawed replated DCs
were able to maintain their IL-12p70 production at
similar levels as fresh DCs until 12 h, but some reduc-
tion was seen compared to 16 h fresh DCs. These
Table 2 DC viability following two different harvesting
methods.
Harvesting method % viable DC (± SEM)
Trypsinization 79.94 ± 3.66 ***
Cold PBS + scraping 59.47 ± 2.44
Trypsinization method yielded higher % of viable DCs compared to harvesting
DCs with cold DPBS and scraping. Fresh monocytes were cultured in CellGenix
DC media supplemented with 2% human AB serum for 4 days. Then
immature DCs were loaded with oxidized tumor lysate for 20 to 24 h followed
by maturation with LPS and IFN-g for 16 h. The percentage of viable DC was
determined by Trypan blue exclusion using the following formula: (total
number of live non-Trypan blue DCs in all the four big squares of the Bürker
chamber ÷ total number of live and dead DCs counted in the four big
squares of the Bürker chamber) × 100%. Data is mean of 3 independent
experiments (± SEM). *** P = 0.0003; highly significant difference was
observed from cold DPBS + scraping (unpaired Student’s t test).
Table 3 DC viability following cryopreservation in two
different cryomedia.
Cryopreservation method % viable DC (±
SEM)
Infusible cryomedia 92.9 ± 2.57 P = 0.6
(NS)
90% human AB serum + 10%
DMSO
86.5 ± 0.55 P = 0.6
(NS)
No significant difference in the percentage recovery of viable lysate-loaded
DCs cryopreserved in infusible cryomedia or 90% human AB serum with 10%
DMSO was observed post-thawed. Mature lysate-loaded DCs were frozen at 5
×1 0
6 cells per ml in infusible cryomedia or 90% human AB serum plus 10%
DMSO, and thawed 24 h later to determine the % of viable cell recovery. The
% of viable DCs was calculated by Trypan blue exclusion using the following
formula: (total number of live non-Trypan blue DCs in all the four big squares
of the Bürker chamber total number of live and dead DCs counted in the four
big squares of the Bürker chamber) × 100%. Data is the mean of 3
independent experiments (± SEM). P = 0.6 (NS; no significant difference in the
viability of thawed DCs was observed when comparing the use of infusible
cryomedia and 90% human AB serum with 10% DMSO) [unpaired Student’s t
test].
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Page 10 of 16Figure 4 Comparing the phenotype of DCs previously cryopreserved in infusible cryomedia or human AB serum containing 10%
DMSO. (A) Middle panel, DCs that had been cyropreserved with infusible cryomedia showed similar expressions of CD86 and CD1c as fresh DCs
(first panel) and higher CD80, CD40 and MHC Class I levels after being thawed and replated for 24 h in fresh human AB serum-supplemented
CellGenix DC media. Third panel, DCs that were cryopreserved with 90% human AB serum plus 10% DMSO exhibited similar level of CD80,
CD40, MHC Class I and CD1c as fresh DCs. DCs cryopreserved in infusible cryomedia expressed approximately 50% lower levels of HLA-DR (**P =
0.001) compared to fresh DCs. On the other hand, DCs cryopreserved in human AB serum plus 10% DMSO media expressed approximately 80%
lower levels of HLA-DR (**P = 0.004) compared to fresh DCs. Data were from a clinical-scale Nunclon™Δ Surface 1-tray Cell Factory and was
representative of 3 independent research-scales experiments (i.e. DCs from 3 different individuals) in Nunclon™Δ Surface T25 cm
2 flasks. (B)
Summary of flow cytometry results from the mean of 3 independent research-scales experiments in Nunclon™Δ Surface T25 cm
2 flasks (MFI ±
SEM). P values are determined with unpaired Student’s t test. ** denotes P value highly significant.
Figure 5 Time-course of IL-12p70 production by DCs. IL-12p70 was detected from fresh DCs from 6 h post LPS and IFN-g stimulation and
peaked at 16 h. Fresh replated DCs and thawed replated DCs continued to produce IL-12p70 albeit at a lower level than fresh DCs. Data were
the mean of 3 independent experiments (i.e. DCs from 3 different individuals) in duplicates in research-scale Nunclon™Δ Surface T25 cm
2 flasks
± SEM. IL-12p70 concentration is expressed as pg/ml.
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Page 11 of 16results indicated that cryopreservation did not impair
substantially IL-12p70 production from the DCs, and
thawed DCs would be able to continue to produce IL-
12p70 within the first 24 h after administration into
cancer patients. In addition, the viability of the cryopre-
served DCs were monitored after 24 h post-thawed to
give an indication of the actual number of DCs that
might survive in vivo in the patient after DC vaccine
administered. It was found that DCs that had been trea-
ted with LPS and IFN-g over a period of 6 to 16 h, cryo-
preserved in infusible media and thawed, showed
comparable high viability of approximately 80% after 24
h of replating in fresh media (data not shown).
T h er e s u l t sf r o mt h i ss t u d yp r o v i d e da no p t i m i z e d
methodology to produce tumor lysate-pulsed DCs that
can be cultured to produce a mature phenotype, mobi-
lized effectively, and cryopreserved with high viability
while maintaining a robust mature DC phenotype and
IL-12p70 production (summarized in Figure 6). We
further tested the functionality of DCs prepared with
the proposed methodology in mixed leukocyte reactions
(MLRs) and compared the performance of DCs gener-
ated in research-scale T25 cm
2 culture flasks and in a
clinical-scale cell factory system. DCs prepared and
cryopreserved based on the final optimized protocol,
were thawed and tested for their ability to stimulate the
proliferation of allogeneic T cells from three different
individuals. It was found that DCs, whether generated in
a clinical-scale cell factory system or in research-scale
T25 cm
2 culture flasks, were potent in stimulating
robust T cell proliferation of allogeneic T cells in MLR
(Figure 7).
Discussion
Dendritic cell (DC)-based immunotherapy is a promis-
ing approach that has been used for over a decade in
the clinic for treating malignancies. As DC generation
procedures are highly variable and difficult to compare
i nm a n yo ft h e s et r i a l se v e nw i t h i nag i v e nc l i n i c a ls e t -
ting or disease, there is a strong need to establish a
defined set of robust criteria for generating DCs that are
highly immunogenic and effective for the clinic. In this
study we evaluated several important culture parameters
for clinical-scale production that could highly influence
the quality of the DC preparation, phenotype and func-
tion. In the process, choices were made based on
Figure 6 Schematic diagram of optimized DC preparation.
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tions or on obvious practical convenience when results
were similar.
The first parameter investigated was the choice of
media for preparing DCs. Many chemically-defined
serum-free media are available including AIM-V media,
CellGenix DC media and X-VIVO 10, 15 or 20 media.
AIM-V [42-45] and CellGenix DC media [9,34,46] are
selected for comparison because they are extensively
used in DC clinical trials and are available in either
therapeutic or GMP grade. It was observed that imma-
ture fully differentiated DCs generated in serum-free
CellGenix DC media were non-adherent and smaller in
size (similar to that of monocytes) compared to DCs
cultured in serum-free AIM-V media (data not shown).
However, DCs cultured in CellGenix DC media supple-
mented with 2% AB human serum showed larger size
and exhibited the most favorable immunophenotype
after lysate-loading and maturation with LPS and IFN-g.
These DCs expressed the highest levels of CD86 and
DC-LAMP combined with low CD14 when compared to
DCs cultured in other media conditions. These DCs also
produced high amounts of IL-12p70 upon maturation.
Although serum supplementation was not required for
AIM-V media, as DCs generated in both serum-free and
serum-supplemented AIM-V media were similar pheno-
typically, DCs generated in CellGenix DC media
required serum supplementation to achieve optimal phe-
notype. The latter also showed significantly higher viabi-
lity. Thus, CellGenix DC media supplemented with 2%
Figure 7 Mixed leukocyte reaction capability of optimized DCs. DCs generated from clinical-scale Nunclon™Δ Surface 1-tray Cell Factory
and DCs generated from research-scale Nunclon™Δ Surface T25 cm
2 flasks using the optimized protocol depicted in Figure 6 were equally
potent in stimulating robust mixed leukocytes reactions from 3 different individuals’ T cells.
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Page 13 of 16human AB serum was chosen as the preferred media
based on favorable DC size and immunophenotype, high
IL-12p70 production and viability.
The second parameter investigated was the type of cell
factory to use. Cell factories are especially suitable for
clinical-scale production of DCs as they could be easily
adapted in a GMP closed-culture system to avoid con-
tamination, and be stacked to maximize space in the
incubators. Each brand of cell factory may have different
surface coating properties that could affect DC differen-
tiation and maturation. Three commercially available
cell factories were investigated- 1) Nunclon™Δ Surface
1-tray Cell Factories, 2) Corning
® CellSTACK
® culture
chambers and 3) Corning
® cell culture ultra-low attach-
ment CellSTACK
® chamber. It was observed that DCs
cultured in Nunclon™Δ Surface exhibited a more favor-
able immunophenotype with significantly higher DC-
LAMP and lower CD14 expression compared to DCs
cultured with Corning
® cell-culture surface after lysate-
loading and stimulation with LPS and IFN-g.I n t e r e s t -
ingly, DCs generated using Corning
® ultra-low attach-
ment surface did not mature properly with LPS and
IFN-g. These DCs showed lower CD86 and HLA-DR
expression compared to DCs that were generated using
t h es a m et y p eo fm e d i ab u tw i t hN u n c l o n ™Δ Surface,
thus highlighting the importance of DC attachment for
proper differentiation and maturation in our cultures.
This may also have important implications when consid-
ering the use of gas permeable culture bags where DCs
bind less firmly to the bag surface compared to polystyr-
ene-coated tissue culture surfaces. Additional work is
required to optimize DC generation under less adhesive
conditions especially with respect to IL-12p70 produc-
tion [47]. In view of these findings, use of polystyrene
Nunclon™Δ Surface is preferred.
At the completion of preparation, most of the mature
lysate-loaded DCs were firmly attached to the flask or
chamber surface. Hence a mean to harvest these DCs
was required. The third parameter was to compare two
commonly used methods for cell harvesting - by enzy-
matic mobilization or by incubation with cold DPBS for
30 min at 4°C followed by cell scraping. It was found
that DCs were still strongly adhered to the culture flasks
or cell factories after incubation with cold DPBS for 30
min at 4°C. Cold DBPS incubation alone was ineffective
in detaching DCs and cell scraping was necessary. Cell
scraping is a harsh physical method that can potentially
damage important cell surface molecules and cause high
rate of cell death. Indeed, only about 50% of DCs was
viable after cell scraping. It is also not feasible to use in
cell factories. The TrypLE™ Select is a recombinant
trypsin that has similar kinetics and cleavage specificity
as animal trypsin. It is produced in a controlled bacterial
fermentation process that is completely free of animal-
and human-derived components, thus minimizing the
potential of contamination by mammalian pathogens.
This property makes it highly suitable for use in DC
preparations for the clinic. As TrypLE™ Select has the
same biological activity as animal trypsin, i.e. to cleave
adhesion molecules, there are concerns that important
molecules such as HLA-DR and MHC class I required
for T cell activation could be cleaved off from the DC
surface. Although these molecules were detected at a
somewhat lower level on DCs that had been treated
with TrypLE™ Select compared to DCs treated with
DPBS and cell scraping, these differences were not sig-
nificant. However, enzymatically mobilized DCs had
higher viability (82%) compared to DCs mobilized with
scraping (50%). Importantly, enzymatically mobilized
DCs were as capable as DCs that were detached with
scraping to present HER-2/neu and MART-1 peptides
at a low concentration (down to 0.1 μg/ml) to HER-2/
neu and MART-1 specific T cells, respectively. Thus
TrypLE™ Select was suitable for use to detach DCs
without compromising the DCs viability or antigen pre-
sentation function.
DC therapy usually involves multiple rounds of vacci-
nation and it can become very laborious to culture fresh
DCs each time. Thus, DC cryopreservation is a highly
desirable approach to minimize labor, time and costs of
manufacturing. The feasibility of generating lysate-
pulsed matured DCs in large numbers and cryopreser-
ving them in -150°C until needed was assessed. Infusible
cryomedia was compared to human AB serum plus 10%
DMSO for freezing and storing lysate-pulsed mature
DCs. It was found that the percentage of viable DCs
obtained from cryopreservation with either infusible
cryomedia or human AB serum was very similar (92.9%
and 86.5%, respectively). These DCs also produced very
similar levels of IL-12p70 after being thawed (not
shown). However, infusible cryomedia was selected as
the choice of freezing and storing DCs, since it contains
less DMSO (7.5%) and it has been used in adoptive T
cell therapy protocols, where thawed T cells were
directly infused into patients without further washing
[48]. Although the presence of small amount of DMSO
is safe for patient administration and may not interfere
with the function of T cells infused directly intrave-
nously, in the case of DCs injected intradermally or
intranodally, it is likely optimal to wash the thawed DCs
twice with HBSS before administrating to patients.
In summary, several important clinical-scale para-
meters have been determined in this study - a) culturing
DCs with GMP-grade CellGenix DC media supplemen-
ted with 2% human AB serum in NunclonΔ surface cell
factory yielded DCs with the most favorable immuno-
phenotype and high IL-12p70 production; b) 500 IU/ml
GM-CSF and 250 IU/ml IL-4 was optimal for DC
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vesting DCs without impacting on DC viability and
function; d) 6 to 9 h of DC stimulation with LPS and
IFN-g produced high level of IL-12p70, which continued
after the cryopreserved DCs were thawed and replated
for 24 h; and finally e) DCs cryopreserved with infusible
cryomedia had high viability after being thawed and
continued to produce high IL-12p70 for 24 h. Using the
DC culture parameters determined above, a set of
robust criteria based on DC phenotype (e.g. CD86,
HLA-DR and CD14), IL-12p70 production in vitro and
MLR for DC-vaccine immunogenicity could be pro-
posed. Additional maturation/activation markers such as
CD40, CD80, MHC Class I and CCR7 can be deter-
mined to give a more complete phenotypic profile of
the DCs. Currently, this optimized method is being
tested in a pilot phase clinical trial of autologous HOCl-
oxidized tumor lysate-pulsed DC in patients with recur-
rent ovarian, primary peritoneal or fallopian tube cancer
(NCT01132014) at the University of Pennsylvania
Hospital.
Conclusions
In this study, different culture parameters for clinical-
scale DC preparation were optimized, including culture
media, type of cell factory surface, method of harvesting
DCs, type of cryomedia for freezing and storing DCs,
and the duration of activating DCs with LPS and IFN-g.
T h ep r o p o s e df i n a lD C - v a c c i n ep r o d u c ts h o u l de x p r e s s
high levels of CD86 and HLA-DR, and low CD14. In
addition, the DCs should be capable of producing IL-
12p70 and be able to stimulate robust MLR in vitro.
The optimized parameters determined in this study
would further facilitate the development of a reference
protocol for clinical-scale production of whole tumor
lysate DC vaccines that is applicable to many forms of
cancers.
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